Malignant Hematology Trials

Malignant Hematology

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


ADCT-402-103  NCT03684694

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma L. Bryan Julie Stiefel Large B-Cell Lymphoma and Mantle Cell Lymphoma Ib

5F9003 NCT02953509 

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma L. Bryan Julie Stiefel Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Ib/II

VT3996-201  NCT03397706

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies Protocol Type: Treatment L. Bryan Julie Stiefel Epstein-Barr Virus Associated Lymphoid Malignancies Ib/II

PrE0404  NCT03323151

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma L. Bryan Julie Stiefel Mantle Cell Lymphoma I/II

NU-16H07  NCT03077828 

(NU-16H07) Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma L. Bryan Julie Stiefel Hodgkin Lymphoma II

BST002  NCT03435848

A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy V. Kota Patricia Loveday AML IIb

A051301 NCT02443077

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype L. Bryan Julie Stiefel Large B-Cell Lymphoma III

EA4151 NCT03267433

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission S. Ghamande Julie Stiefel Mantle Cell Lymphoma III

FEDR-MF-001  NCT03755518

A Phase 3B, Multicenter, Single-Arm, Open-Label Safety and Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib V. Kota Patricia Loveday Myelofibrosis III

INCB-39110-309  NCT03584516

A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease V. Kota Patricia Loveday Chronic Graft-Versus-Host Disease III

Ponatinib-3001  NCT03589326

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Protocol V. Kota Patricia Loveday Acute Lymphoblastic Leukemia III

B1761031 ClinicalTrials.govNCT03727750 

A Single Arm, Open-label, Phase 4 Study Evaluating Qt Interval, Pharmacokinetics, And Safety Of Gemtuzumab Ozogamicin (Mylotarg (Trademarked)) as a Single-agent Regimen in Patients With Relapsed or Refractory Cd33-positive Acute Myeloid Leukemia V. Kota Patricia Loveday Acute Myeloid Leukemia IV